S223: REAL-WORLD EARLY OUTCOMES OF AXICABTAGENE CILOLEUCEL FOR RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

S223: REAL-WORLD EARLY OUTCOMES OF AXICABTAGENE CILOLEUCEL FOR RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

Bibliographic Details
Main Authors:	Caron Jacobson, Michael T. Hemmer, Zhen-Huan Hu, Matthew Frank, Leslie Popplewell, Nausheen Ahmed, Yi Lin, Timothy Best, Sara Beygi, Harry Miao, Christine Fu, Fang Sun, Hairong Xu, Marcelo Pasquini
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000967804.31464.ce

Similar Items

P1111: COMPARATIVE EFFICACY AND SAFETY OF TISAGENLECLEUCEL AND AXICABTAGENE CILOLEUCEL IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
by: M. Dickinson, et al.
Published: (2022-06-01)

Cost-effectiveness of treating relapsed or refractory 3L+ follicular lymphoma with axicabtagene ciloleucel vs mosunetuzumab in the United States
by: Olalekan O. Oluwole, et al.
Published: (2024-05-01)

Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response
by: Andrew P. Jallouk, et al.
Published: (2022-11-01)

P1107: ZUMA-22: A PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD-OF-CARE THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
by: Ian W. Flinn, et al.
Published: (2023-08-01)

Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas
by: Peter A. Riedell, et al.
Published: (2020-01-01)

Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma
by: Jennifer M. Logue, et al.
Published: (2020-04-01)

The role of axicabtagene ciloleucel as a treatment option for patients with follicular/marginal zone lymphoma
by: Jose Sandoval-Sus, et al.
Published: (2021-05-01)

Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma
by: Crystal Mackall, et al.
Published: (2024-07-01)

P1398: AXICABTAGENE CILOLEUCEL VERSUS TISAGENLECLEUCEL CAR-T CELLS IN RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
by: Nico Gagelmann, et al.
Published: (2023-08-01)

The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel
by: Kitsada Wudhikarn, et al.
Published: (2021-07-01)

Axicabtagene Ciloleucel in the Management of Follicular Lymphoma: Current Perspectives on Clinical Utility, Patient Selection and Reported Outcomes
by: Mohty R, et al.
Published: (2023-04-01)

P1204: AXICABTAGENE CILOLEUCEL VEIN-TO-VEIN TIME IN TRIAL OR REAL-WORLD SETTINGS VS OTHER CAR T-CELL THERAPIES FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS
by: Frederick Locke, et al.
Published: (2023-08-01)

Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
by: Mi Kwon, et al.
Published: (2022-06-01)

Exacerbations of Persistent Neurotoxicity following Axicabtagene Ciloleucel in a Patient with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Case Report
by: Graeme A. Fenton, et al.
Published: (2024-01-01)

Human Herpesvirus 6 Encephalitis Following Axicabtagene Ciloleucel Treatment for Refractory Diffuse Large B Cell Lymphoma
by: Mili Shah, et al.
Published: (2021-03-01)

P1203: EFFICACY AND SAFETY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) FOR THE TREATMENT OF RELAPSE/REFRACTORY NON-HODGKIN LYMPHOMA: FIRST REAL-WORLD DATA IN CHINESE POPULATION
by: LI Wang, et al.
Published: (2023-08-01)

Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma
by: Jain MD, et al.
Published: (2018-05-01)

Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma
by: Paolo Strati, et al.
Published: (2020-07-01)

PB2346: ZUMA-24: A PHASE 2, OPEN-LABEL, MULTICENTER STUDY OF AXICABTAGENE CILOLEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA GIVEN WITH CORTICOSTEROIDS IN THE OUTPATIENT SETTING
by: Lori Leslie, et al.
Published: (2023-08-01)

P1197: AXICABTAGENE CILOLEUCEL (AXI-CEL) IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): OUTCOMES OF THE PHASE 2 ZUMA-14 STUDY
by: P. Strati, et al.
Published: (2022-06-01)

P1694: COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL VS. TISAGENLECLEUCEL FOR THE TREATMENT OF RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: UPDATED SURVIVAL RESULTS FROM THE ZUMA-1 AND JULIET TRIALS
by: Olalekan Oluwole, et al.
Published: (2023-08-01)

P1198: ASSOCIATION OF PRETREATMENT TUMOR CHARACTERISTICS AND CLINICAL OUTCOMES FOLLOWING SECOND-LINE AXICABTAGENE CILOLEUCEL VS STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
by: F. L. Locke, et al.
Published: (2022-06-01)

S211: CLINICAL AND PATIENT-REPORTED OUTCOMES IN A PHASE 3 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VS STANDARD-OF-CARE IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (ZUMA-7)
by: A. Sureda, et al.
Published: (2022-06-01)

Efficacy and Safety of Axicabtagene Ciloleucel and Tisagenlecleucel Administration in Lymphoma Patients With Secondary CNS Involvement: A Systematic Review
by: XiaoQin Wu, et al.
Published: (2021-07-01)

Acute patient‐reported outcomes in B‐cell malignancies treated with axicabtagene ciloleucel
by: Aasha I. Hoogland, et al.
Published: (2021-03-01)

S260: A MATCHED COMPARISON OF TISAGENLECLEUCEL AND AXICABTAGENE CILOLEUCEL CAR T CELLS IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A REAL-LIFE LYSA STUDY FROM THE FRENCH DESCAR-T REGISTRY
by: E. Bachy, et al.
Published: (2022-06-01)

EFFICACY AND SAFETY OF EXPERIMENTAL CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS VERSUS AXICABTAGENE CILOLEUCEL (YESCARTA) FOR THE TREATMENT OF RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: MATCHING ADJUSTED INDIRECT COMPARISONS AND SYSTEMATIC REVIEW
by: B Weinstein, et al.
Published: (2021-10-01)

Cost-effectiveness analysis of axicabtagene ciloleucel as a second-line treatment for diffuse large B-cell lymphoma in China and the United States
by: Na Li, et al.
Published: (2023-05-01)

A Pharmacovigilance Study on the Safety of Axicabtagene Ciloleucel Based on Spontaneous Reports from the EudraVigilance Database
by: Concetta Rafaniello, et al.
Published: (2023-08-01)

Digital PCR Assays for Precise Quantification of CD19-CAR-T Cells after Treatment with Axicabtagene Ciloleucel
by: Boris Fehse, et al.
Published: (2020-03-01)

The Association Between Glucocorticoid Administration and the Risk of Impaired Efficacy of Axicabtagene Ciloleucel Treatment: A Systematic Review
by: Zhen Sun, et al.
Published: (2021-04-01)

Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity
by: William G. Breen, et al.
Published: (2023-08-01)

The prognostic value of POD24 in relapsed/refractory follicular lymphoma—A SCHOLAR‐5 analysis
by: Eve H. Limbrick‐Oldfield, et al.
Published: (2025-02-01)

The role of tazemetostat in relapsed/refractory follicular lymphoma
by: Gottfried von Keudell, et al.
Published: (2021-05-01)

Tumor gene expression signatures associated with outcome in large B−cell lymphoma treated with CD19-directed CAR T−cell therapy (axicabtagene ciloleucel)
by: Yuan Tian, et al.
Published: (2025-02-01)

Axicabtagene ciloleucel in non-Hodgkin lymphoma: the restricted mean survival time as a tool for estimating progression-free life expectancy better than the median
by: Andrea Messori, et al.
Published: (2020-06-01)

Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis
by: Ahmed Abbasi, et al.
Published: (2020-01-01)

PB2319: ZUMA-23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYMPHOMA
by: Jason Westin, et al.
Published: (2023-08-01)

Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow up
by: Andrew J. Portuguese, et al.
Published: (2025-03-01)

Treatment selection for patients with relapsed or refractory follicular lymphoma
by: Alan Z. Skarbnik, et al.
Published: (2023-03-01)